For smaller-volume, at-home administration, Halozyme highlighted Hypercon and Surf Bio, which management said can enable hyperconcentration of therapeutics up to approximately 500 mg/mL—potentially reducing injection volumes to less than 2 mL or into a 2 mL to 10 mL range that could fit either a small-volume autoinjector or Halozyme’s proprietary high-volume autoinjector.Torley also pointed to two areas of emerging interest for ENHANZE: potential applications with nucleic acids (including interest in lipid ...